elagolix sold brand name orilissa gonadotropinreleasing hormone antagonist gnrh antagonist medication used treatment pain associated endometriosis also development treatment uterine fibroids heavy menstrual bleeding medication investigation treatment prostate cancer enlarged prostate men well development conditions elagolix taken mouth twice per taken months depending side effects elagolix include menopausallike symptoms hot flashes night sweats insomnia amenorrhea mood changes anxiety decreased bone density among elagolix gnrh antagonist antagonist gonadotropinreleasing hormone receptor gnrhr biological target hypothalamic hormone gonadotropinreleasing hormone blocking gnrhr dosedependently suppresses gonadal production hence circulating levels sex hormones estradiol progesterone elagolix shortacting gnrh antagonist used achieve either partial substantial suppression sex hormone reduced estrogen levels endometrium responsible efficacy elagolix treatment elagolix first described approved medical use july described secondgeneration gnrh modulator due nonpeptide smallmolecule nature oral unlike gnrh agonists older gnrh antagonists peptides firstgeneration gnrh modulators elagolix gnrh analogue structurally related elagolix first secondgeneration orally active gnrh modulator introduced medical introduction elagolix united states canada followed relugolix brand name relumina next secondgeneration gnrh antagonist japan january us food drug administration fda considers firstinclass elagolix used treatment moderate severe pain associated endometriosis premenopausal endometriosis condition endometrium inner lining uterus grows outside uterus surrounding tissues causes symptoms pelvic pain around women may affected elagolix significantly decreases symptoms dysmenorrhea menstrual pelvic pain nonmenstrual pelvic pain dyspareunia pain sexual intercourse women medication used lower dosage mg per day higher dosage mg twice per day depending severity effectiveness elagolix treatment symptoms endometriosis demonstrated elaris endometriosis ii emi emii phase iii clinical elaris emi percentage women clinical response respect dysmenorrhea lowerdose elagolix group higherdose elagolix group compared placebo group elaris emii corresponding percentages compared p elaris emi percentage women clinical response respect nonmenstrual pelvic pain lowerdose elagolix group higherdose elagolix group compared placebo group p comparisons elaris emii corresponding percentages compared p p reductions symptoms endometriosis elagolix resulted improved quality duration use elagolix treatment endometriosis limited due progressive risk bone loss lowest effective dosage elagolix used months mg per day dosage months mg twice per day relatively short duration elagolix taken approximately time case twicedaily administration elagolix taken approximate intervals instance morning taken without elagolix approved treatment approved offlabel uses gnrh antagonists general gnrhr desensitization therapy gnrh agonists leuprorelin include uterine fibroids breast cancer premenopausal women prostate cancer men precocious puberty children hormone therapy transgender adolescents adults among elagolix available form orilissa mg oral mg tablets light pink oblong filmcoated el debossed one side mg tablets light orange oblong filmcoated el debossed one inactive ingredients tablets include mannitol sodium carbonate monohydrate pregelatinized starch povidone magnesium stearate polyvinyl alcohol titanium dioxide polyethylene glycol talc distinct color additive carmine high tint mg tablets iron oxide red mg contraindications elagolix include pregnancy known osteoporosis severe hepatic impairment concomitant use strong organic aniontransporting polypeptide oatp inhibitors ciclosporin elagolix may increase risk miscarriage early women avoid pregnancy taking elagolix instance using birth control discontinue medication become wish become elagolix used women osteoporosis may increase risk bone severe hepatic impairment associated increased exposure elagolix may increase risk bone women moderate hepatic impairment associated increased exposure elagolix medication mg twice per day used mg per day used inhibitors likely greatly increase exposure elagolix similarly moderate severe hepatic combined birth control contraindicated elagolix estrogen component expected decrease effectiveness elagolix treatment endometriosis hence forms birth control nonhormonal birth control used elagolix contraindicated women breastfeeding unknown whether medication excreted breast milk adverse effects milk production breastfed use elagolix women breastfeeding considered carefully weighing benefits side effects elagolix general similar menopausal common side effects elagolix incidence hot flashes night sweats headaches nausea amenorrhea cessation next frequent side effects elagolix incidence insomnia anxiety arthralgia joint pain depression mood less common side effects elagolix incidence include decreased sex drive diarrhea abdominal pain weight gain dizziness constipation common side effects elagolix include decreased bone mineral density bmd changes blood lipid rare serious adverse effects observed elagolix therapy clinical trials included appendicitis abdominal pain back pain though unknown due serious adverse effects elagolix may include bone loss miscarriage suicidality elevated liver elagolix discontinued due side effects women clinical trials common reasons hot flashes night sweats nausea decreased elagolix dose durationdependently decreases bmd premenopausal women longterm months treatment elagolix lumbar spine bmd decreased mg per day mg twice per decrease bmd elagolix therapy may fully reversible discontinuation partial recovery observed months discontinuation cause decrease bmd elagolix estrogen deficiency analogous associated consequences effects elagolix bmd unknown may increase risk bone loss duration use elagolix women risk factors bone loss osteoporosis history lowtrauma fracture assessment bmd may elagolix used premenopausal women known supplementation calcium andor vitamin treatment elagolix studied may beneficial helping maintain bone elagolix decreases amount intensity duration menstrual amenorrhea cessation menstruation observed women mg per day women mg twice per day compared less women given decreased menstrual bleeding caused elagolix may impede ability recognize pregnancy timely based mechanism action elagolix may increase risk miscarriage early pregnancy discontinued pregnancy pregnancy suspected pregnancy testing elagolix decreases rate ovulation thereby decreases likelihood pregnancy shown fully effective contraceptive relied prevent incidence depression mood changes clinical trials elagolix increased premenopausal women taking elagolix relative mood depressiontype side effects altered mood mood swings depressed mood depression depressive symptoms tearfulness occurred women mg per day women mg twice per day compared women given suicidal ideation behavior occurred women one suicide people taking elagolix new existing depressive symptoms promptly evaluated determine whether benefits treatment outweigh new existing depressive symptoms referral mental health professional appropriate may immediate medical attention sought suicidal ideation elagolix dosedependently produced elevated liver enzymes including elevations serum alanine aminotransferase least upper limit clinical observed one woman mg per day five women mg twice per day compared one woman given medical attention sought signs symptoms liver injury jaundice lowest effective dosage elagolix may used minimize risk liver problems develop elevated liver enzymes elagolix therapy prompt evaluation done determine whether benefits treatment outweigh event overdose elagolix person monitored signs symptoms adverse reactions treated symptomatic basis elagolix assessed clinical studies dose high single administration mg resulted concentrations medication times higher typical high clinical dosage mg twice per adverse effects chronic overdosage elagolix may result greater suppression estradiol levels consequent increased risk bone loss longterm elagolix number potential drug interactions elagolix substrate cytochrome enzyme inhibitors inducers may alter metabolism elagolix increase decrease circulating strong inhibitor ketoconazole found increase peak levels total exposure single mg dose elagolix paradoxically rifampin strong inducer enzymes increased peak levels total exposure single mg dose elagolix single dose rifampin increased peak levels elagolix total exposure whereas continuous rifampin therapy increased peak levels elagolix total exposure use elagolix mg twice per day concomitantly rifampin recommended whereas concomitant use elagolix mg per day rifampin limited significant changes exposure elagolix observed concomitant administration rosuvastatin substrate bcrp sertraline moderate inhibitor fluconazole strong inhibitor moderate inhibitor elagolix substrate hepatic levels elagolix found increased people genotype characterized reduced transporter concomitant use elagolix medications inhibit may increase elagolix levels use elagolix strong inhibitors like ciclosporin gemfibrozil may markedly increase elagolix exposure elagolix weak moderate inducer may decrease levels medications substrates addition elagolix inhibitor pglycoprotein may increase levels medications substrates pglycoprotein elagolix found increase exposure digoxin ethinylestradiol whereas found decrease exposure rosuvastatin midazolam norethisterone norelgestromin combined birth control pills forms combined birth control contain estrogen elagolix treats endometriosis decreasing estrogen levels endometrium form hormonal birth control likely expected decrease effectiveness elagolix treatment effect progestogenonly birth control effectiveness elagolix endometriosis however progestogens antiestrogenic uterus highdose progestin therapy known effective treatment endometriosis similarly gnrh basis limited clinical research combined birth control pills also found effective treatment endometriosis likely effective gnrh modulator advised women use nonhormonal methods birth control elagolix therapy one week following discontinuation elagolix acts potent selective competitive antagonist gonadotropinreleasing hormone receptor gnrhr biological target hypothalamic peptide hormone gonadotropinreleasing hormone gnrh affinity kd elagolix gnrhr blocking gnrhr pituitary gland elagolix suppresses gnrhinduced secretion gonadotropins luteinizing hormone lh folliclestimulating hormone fsh anterior pituitary thereby decreases production sex hormones women elagolix dosedependently suppresses production ovarian hormones including estradiol progesterone testosterone thereby decreases circulating levels men gnrh modulators suppress testicular production testosterone estradiol decreasing circulating levels hormones unlike previous gnrh agonists antagonists referred collectively gnrh analogues elagolix nonpeptide smallmolecule compound taken estrogens like estradiol stimulate growth endometrium thereby aggravate symptoms suppressing estrogen production levels elagolix decreases growth endometrium decreases endometriosis symptoms pelvic elagolix shortacting gnrh antagonist terminal halflife typically short duration elagolix body activation gnrhr gnrh fully blocked throughout day oncedaily administration result gonadotropin sex hormone levels partially suppressed elagolix taken per addition degree suppression dosedependently adjusted needed instance higherdose twicedaily administration achieve greater hormonal short duration body effects elagolix rapidly reversible upon addition due partial incomplete suppression estradiol levels side effects elagolix hot flashes decreased bmd lower firstgeneration gnrh clinical trials elagolix produced dosedependent decreases gonadotropin estradiol progesterone levels median levels estradiol partially suppressed pgml follicular phase levels mg daily fully nearfully suppressed pgml postmenopausal levels mg twice study premenopausal women effects elagolix fsh levels found maximal dosage mg twice per day whereas effects lh estradiol levels maximal dosage mg twice per day levels progesterone maintained anovulatory levels ngml across study period dosages elagolix mg twice per day dosage elagolix mg twice per day appears produce greater suppression gonadotropin estradiol levels dosage mg twice per day premenopausal suppression gonadotropin sex hormone levels elagolix occurs rapidly within hours upon discontinuation elagolix gonadotropin sex hormone levels remain suppressed least hours show recovery within consequence suppression gonadotropin sex hormone levels elagolix inhibits ovulation course three menstrual cycles ovulation rate elagolix mg daily mg twice ovulation triggered surge estradiol levels midcycle estrogen exposure elagolix therapy might greater around time addition activity gnrh antagonist elagolix weak moderate inducer inhibitor result elagolix may affect metabolism andor transport medications may contribute drug interactions elagolix taken oral route administration contrast gnrh oral bioavailability elagolix humans described food drug administration fda label medication animal research elagolix showed low oral bioavailability rats following administration elagolix rapidly absorbed peak concentrations occurring drug accumulation ratio elagolix mg per day mg twice per day indicating accumulated body continuous steady state peak levels elagolix mg per day ngml mg twice per day ngml areaunderthecurve levels elagolix mg per day mg twice per day toxicology study found levels elagolix women single dose mg times higher women taking mg twice taking elagolix highfat meal found decrease peak levels areaunderthecurve levels terms distribution plasma protein binding elagolix bloodtoplasma ratio volume distribution steady state l mg per day l mg twice per elagolix metabolized liver major pathway minor pathways including terminal halflife elagolix typically study found halflife hours single dose hours continuous oral clearance elagolix lhour mg per day lhour mg twice per major pathway elimination elagolix hepatic elagolix taken circulation liver hepatic people two reduced function alleles gene encodes cc genotype plasma levels elagolix found increased relative people normal function frequency reduced function genotype generally less racial ethnic elagolix excreted less urine exposure elagolix affected renal impairment mild hepatic impairment increased approximately women moderate hepatic impairment approximately women severe hepatic differences pharmacokinetics elagolix individuals different racial ethnic similarly pharmacokinetics elagolix unaffected body weight body mass peak areaunderthecurve levels elagolix shown altered inhibitors like ketoconazole inducers like inhibitors may increase circulating levels elagolix elagolix considered contraindicated combination strong elagolix substrate pglycoprotein effect inhibitors inducers pglycoprotein pharmacokinetics elagolix elagolix inhibitor elagolix smallmolecule nonpeptide contrast gnrh analogues leuprorelin cetrorelix peptides analogues smallmolecule nonpeptide orally active gnrh antagonists besides elagolix include linzagolix opigolix relugolix sufugolix although none compounds introduced medical use elagolix used elagolix sodium sodium salt white white light yellow compound freely soluble chemical name elagolix sodium sodium molecular formula molecular weight free acid form elagolix molecular formula molecular weight elagolix first described literature originally developed pharmaceutical company neurocrine biosciences later developed together neurocrine biosciences abbvie previously abbott june neurocrine biosciences abbott announced global agreement develop commercialize elagolix treatment medication completed phase iii clinical trials endometriosis november two phase iii clinical trials elaris endometriosis ii emi emii studies studies included almost women treated september abbvie filed new drug application nda elagolix treatment pain associated endometriosis united medication approved fda treatment endometriosisassociated pain united states july first new medication approved fda treatment endometriosis elagolix first member new class gnrh modulators described secondgeneration due nonpeptide smallmolecule nature oral activity second member group relugolix brand name relumina introduced japan january addition endometriosis elagolix development treatment uterine fibroids phase iii clinical trials elagolix generic name drug inntooltip international nonproprietary name usantooltip united states adopted also known former developmental code names elagolix marketed brand name elagolix available united states similar medication relugolix available prior introduction elagolix estimated cost per available generic medicationcitation needed november elagolix phase iii clinical trials treatment uterine fibroids uterine leiomyoma menorrhagia abnormally heavy bleeding menstruation efficacy safety study elagolix combination addback estradiol estrogen norethisterone acetate progestin treatment menorrhagia associated uterine fibroids premenopausal women medication also investigation treatment prostate cancer benign prostatic hyperplasia enlarged prostate men development indications antagonists pegvisomant httpsenwikipediaorgwikielagolix